智通财经APP获悉，复锐医疗科技(01696)再跌近5%，该股昨日重挫逾13%。截至发稿，跌4.81%，报5.74港元，成交额1656.45万港元。
消息面上，复锐医疗科技日前发布2025年中期业绩，收益1.65亿美元，同比下降1.9%；母公司拥有人应占溢利642.6万美元，同比下降41.3%。公告指出，期内集团收益同比减少，主要归因于北美市场状况充满挑战，包括高利率及消费疲软。此外，六月因地区紧张局势令运输受限，导致收益确认略有延迟。若不计北美市场不利因素，与2024年同期相比，复锐医疗科技国际市场实现7.1%增长。
申万宏源表示，公司北美市场受高利率及消费疲软冲击，收益下滑明显，拖累整体业绩；而北美以外国际市场凭借直销办公室布局，实现7.1%增长。该行认为，作为能量源医美器械头部企业，公司依托直销网络强化亚太优势，注射填充业务打开第二增长曲线。短期北美拖累不改长期逻辑，达希斐上市及联合治疗生态放量有望驱动下半年业绩反弹。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.